Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesA Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Clinical Cancer Research, 10/15/09
Burris HA et al. – Lapatinib was well tolerated following once and twice daily administration. Systemic exposure to lapatinib was dependent on the dose, duration and frequency of dosing, and prandial state. Clinical activity was observed.
Related Articles
Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
Expert Review of Anticancer Therapy, 11/12/09
Relevance Score: 67%
Lapatinib in metastatic breast cancer
Women's Health, 10/30/09
Relevance Score: 67%
Informing the debate on oral health care for older people: a qualitative study of older peoples views on oral health and oral health care
Gerodontology, 10/12/09
Relevance Score: 48%
Oral health-related quality of life of 12- and 15-year-old Thai children: findings from a national survey
Community Dentistry and Oral Epidemiology, 11/13/09
Relevance Score: 46%
Oral or transdermal opioids for osteoarthritis of the knee or hip
Cochrane Reviews, 10/13/09
Relevance Score: 46%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Clinical Cancer Research, 12/01/09
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 12/01/09
Sponsor
Article Search
Sponsor